Michael R Hamblin Ph.D. was a Principal Investigator at the Wellman Center for Photomedicine at Massachusetts General Hospital, an Associate Professor of Dermatology at Harvard Medical School and is now a Distinguished Visiting Professor at the University of Johannesburg, South Africa. He gained his PhD in organic chemistry from Trent University in England.

His research interests include photodynamic therapy, photobiomodulation drug delivery, nanomedicine, and tissue engineering. His research program was supported by NIH, CDMRP, USAFOSR and CIMIT. He has published over 560 peer-reviewed articles, over 150 conference proceedings, book chapters and International abstracts and holds 10 patents. He is Editor-in Chief of “Photobiomodulation, Photomedicine and Laser Surgery”, Associate Editor for 10 journals, on the editorial board of a further 20 journals.

He has an h-factor 113 and 52,000 citations. He has authored/edited 25 textbooks on PDT and photomedicine including 13 SPIE proceedings. Dr Hamblin was elected as a Fellow of SPIE in 2011, received the 1st Endre Mester Lifetime Achievement Award from NAALT in 2017, the Outstanding Career Award from the Dose Response Society, and the 1st Ali Javan award for Photobiomodulation Basic Science Research from WALT in 2018.


This talk was part of Synchrony 2020 Online Symposium - 'From Bench to Biopharma', organised by the The BRAIN Foundation in partnership with UC Davis MIND Institute and CalTech.

For more Synchrony 2020 talks and highlights: [ Ссылка ]

🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠

Synchrony [ Ссылка ] is the first and only international symposium on translational research in #autism, that brings together academia, #biotech, pharmaceutical companies and #venture partners from around the world with the mission to improve health and quality of life of people with #autismspectrumdisorder.

🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠

The BRAIN Foundation [ Ссылка ] is a 501c(3) non-profit. The founders of BRAIN envision a world where every child and adult on the autism spectrum is healthy, participates fully in education and employment, and has a better quality of life. It aims to catalyze research that results in evidence-based interventions for the disabilities associated with autism, and also results in better medical standard of care.

To accomplish this, it funds impactful research through #philanthropy and our network of partners in the venture, corporate, and grassroots community.

свернуть